Robert W. Baird Remains a Buy on Marinus (MRNS)

By Austin Angelo

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Marinus (MRNSResearch Report) on May 17 and set a price target of $32.00. The company’s shares closed last Wednesday at $14.77.

According to TipRanks.com, Skorney is a 3-star analyst with an average return of 3.8% and a 48.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Marinus has an analyst consensus of Strong Buy, with a price target consensus of $30.50, representing an 112.4% upside. In a report issued on May 18, Oppenheimer also maintained a Buy rating on the stock with a $32.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.04 and a one-year low of $6.04. Currently, Marinus has an average volume of 277.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.